The intent of the FY22 CPMRP IIRA is to support studies that have the potential to make significant advances in the research, patient care, and/or quality of life in the FY23 CPMRP IIRA Focus Areas. IIRA applications may involve basic, translational, and clinically oriented research, including studies in animal models, research with human anatomical substances, and research with human subjects, as well as correlative studies associated with an existing clinical trial; however, this award may not be used to conduct clinical trials. Multidisciplinary collaborations and innovative approaches are encouraged. Studies seeking to advance new and novel opioid-based therapeutic interventions do not meet the intent of the award mechanism and will not be selected for funding. Studies seeking to understand and reduce opioid utilization in chronic pain management within the context of current prescribing practices are acceptable.
Deadlines:
To meet the intent of the award mechanism, applications must address at least one of the FY23 CPMRP IIRA Focus Areas. Selection of the appropriate focus area is the responsibility of the applicant.
• Chronification of pain ○ Understanding mechanisms of, and developing models for studying, the transition from acute to chronic pain. ○ Development of therapies to prevent and treat chronification ○ Identifying risk or protective factors or biomarkers for treatment response or patient susceptibility to chronification. ○ Investigating relationships between pain and its comorbidities that can contribute to the development/progression of chronic pain
• Development of non-opioid therapies and methods for the treatment of chronic pain o Novel non-mu-opioid pharmacological therapies o Devices or procedures that treat chronic pain directly o Devices or procedures that improve the administration of non-opioid analgesics
Independent Investigators at all levels may be named by the organization as the PI on the application. An eligible PI, regardless of ethnicity, nationality, or citizenship status, must be employed by or affiliated with an eligible organization.
The anticipated direct costs budgeted for the entire period of performance for an FY23 CPMRP Investigator-Initiated Research Award should not exceed $900,000. Refer to Section II.D.5, Funding Restrictions, for detailed funding information.
